Pacific Biosciences of California Inc

Latest Results (10.10.2025):

Pacific Biosciences of California Inc. reported its financial results for the second quarter of 2025, showcasing revenue growth and a reduction in operating expenses compared to the same period in 2024. Despite continuing to operate at a net loss, the company made significant strides in product sales and expanded its market presence.

Revenue Growth

Revenue increased to $39.8 million in Q2 2025 from $36.0 million in Q2 2024, driven by a rise in consumable and service revenues.

Operating Expenses Reduced

GAAP operating expenses decreased significantly to $59.5 million in Q2 2025 from $181.8 million in Q2 2024, while non-GAAP operating expenses also fell to $58.1 million from $71.0 million year-over-year.

Improved Gross Profit Margins

GAAP gross profit rose to $14.7 million in Q2 2025 from $5.9 million in Q2 2024. Non-GAAP gross profit also increased to $15.2 million with a gross margin of 38%, up from 37% the previous year.

Net Loss Narrowed

GAAP net loss for Q2 2025 was $41.9 million, a substantial improvement from $173.3 million in Q2 2024. Non-GAAP net loss also decreased to $40.0 million compared to $55.2 million a year earlier.

Product Sales and Market Expansion

The company sold 15 Revio™ systems and 38 Vega™ systems in Q2 2025, expanding its product footprint. Additionally, Pacific Biosciences strengthened its distribution in China through a new agreement with Haorui Gene.

Strong Cash Position

Cash, cash equivalents, and investments stood at $314.7 million as of June 30, 2025, down from $509.8 million at the end of the previous year.

Strategic Collaborations and Innovations

Pacific Biosciences contributed to the Platinum Pedigree benchmark in Nature Methods and joined the 1000 Genomes Long Read Project, enhancing its role in advancing genomic research.